Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis

Bulletin of the World Health Organization

Volumn 89, Issue 12, 2011, Pages 864-872

  Denning, David W ^a   Pleuvry, Alex ^b   Cole, Donald C ^c  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b Independent pharmaceutical consultant ^*  (United Kingdom)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT;

HEALTH CARE; HEALTH STATUS; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

CHINA; DEMOCRATIC REPUBLIC CONGO; HUMAN; INCIDENCE; INDIA; LUNG ASPERGILLOSIS; LUNG CAVITATION; LUNG TUBERCULOSIS; MORTALITY; NIGERIA; PREVALENCE; REVIEW; SOUTHEAST ASIA; SURVIVAL RATE; TAIWAN; UNITED STATES; WESTERN EUROPE; WORLD HEALTH ORGANIZATION;

ANTIFUNGAL AGENTS; ANTITUBERCULAR AGENTS; EPIDEMIOLOGIC METHODS; HUMANS; INCIDENCE; INVASIVE PULMONARY ASPERGILLOSIS; PREVALENCE; RISK ASSESSMENT; TUBERCULOSIS, PULMONARY; WORLD HEALTH;

CHINA; CONGO; INDIA; NIGERIA; TAIWAN; UNITED STATES;

EID: 82555161638     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.11.089441     Document Type: Review

References (46)

1. Lonnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K, Glaziou P et al. Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet 2010;375:1814-29. doi:10.1016/S0140-6736(10)60483-7 PMID:20488524
2. Global tuberculosis control: epidemiology, strategy, financing: WHO report 2009. Geneva: World Health Organization; 2009.
3. Ross J, Ehrlich RI, Hnizdo E, White N, Churchyard GJ. Excess lung function decline in gold miners following pulmonary tuberculosis. Thorax 2010;65:1010-5. doi:10.1136/thx.2009.129999 PMID:20871124
4. Denning DW. Chronic aspergillosis. In: Latge JP, Steinbach WJ, editors.Aspergillus fumigatus and aspergillosis. Washington: ASM Press; 2009.
5. Jewkes J, Kay PH, Paneth M, Citron KM. Pulmonary aspergilloma: analysis of cavitating invasive pulmonary aspergillosis in immunocompromised patients. Ann Thorac Surg 1983;53:621.
6. Nam HS, Jeon K, Um SW, Suh GY, Chung MP, Kim H et al. Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: a review of 43 cases. Int J Infect Dis 2010;14:e479-82. doi:10.1016/j.ijid.2009.07.011 PMID:19910234
7. Denning DW, Riniotis K, Dobrashian R, Sambatakou H. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 2003;37(Suppl 3):S265-80. doi:10.1086/376526 PMID:12975754
8. Camuset J, Nunes H, Dombret MC, Bergeron A, Henno P, Philippe B et al. Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients. Chest 2007;131:1435-41. doi:10.1378/ chest.06-2441 PMID:17400661
9. Aspergilloma and residual tuberculous cavities-the results of a resurvey. Tubercle 1970;51:227-45. PMID:5495645
10. Tomlinson JR, Sahn SA. Aspergilloma in sarcoid and tuberculosis. Chest 1987;92:505-8. doi:10.1378/chest.92.3.505 PMID:3622028
11. Massard G, Roeslin N, Wihlm JM, Dumont P, Witz JP, Morand G. Surgical treatment of pulmonary and bronchial aspergilloma. Ann Chir 1993;47:141.French PMID:8317872
12. Research Committee of the British Tuberculosis Association. Aspergillusin persistent lung cavities after tuberculosis. A report from the Research Committee of the British Tuberculosis Association. Tubercle 1968;49:1-11. doi:10.1016/S0041-3879(68)80002-9 PMID:5660585
13. International standards for tuberculosis care (ISTC). The Hague: Tuberculosis Coalition for Technical Assistance; 2006.
14. Harries AD, Maher D, Nunn P. An approach to the problems of diagnosing and treating adult smear-negative pulmonary tuberculosis in high- HIV-prevalence settings in sub-Saharan Africa. Bull World Health Orga1998;76:651-62. PMID:10191561
15. Global tuberculosis database [Internet]. Incidence, mortality and percentage pulmonary tuberculosis. Geneva: World Health Organization; Available from: http://apps.who.int/globalatlas/ [accessed 3 August 2011].
16. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol 2005;8:19-32. doi:10.1080/1364557032000119616
17. Hamilton CD, Stout JE, Goodman PC, Mosher A, Menzies R, Schluger NWet al.; Tuberculosis Trials Consortium. The value of end-of-treatment chestradiograph in predicting pulmonary tuberculosis relapse. Int J Tuberc LungDis 2008;12:1059-64. PMID:18713505
18. Lee JJ, Chong PY, Lin CB, Hsu AH, Lee CC. High resolution chest CT in patients with pulmonary tuberculosis: characteristic findings before and after antituberculous therapy. Eur J Radiol 2008;67:100-4. doi:10.1016/j. ejrad.2007.07.009 PMID:17870275
19. de Valliere S, Barker RD. Residual lung damage after completion of treatment for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2004;8:767-71. PMID:15182148
20. Sonnenberg P, Murray J, Glynn JR, Thomas RG, Godfrey-Faussett P, Shearer S. Risk factors for pulmonary disease due to culture-positive M. tuberculosis or nontuberculous mycobacteria in South African gold miners. Eur Respir J2 000;15:291-6. doi:10.1034/j.1399-3003.2000.15b12.x PMID:10706494
21. Bombarda S, Figueiredo CM, Seiscento M, Terra Filho M. Pulmonarytuberculosis: tomographic evaluation in the active and post-treatment phases. Sao Paulo Med J 2003;121:198-202. doi:10.1590/S1516-31802003000500004 PMID:14666291
22. Lillebaek T, Poulsen S, Kok-Jensen A. Tuberculosis treatment in Denmark:treatment outcome for all Danish patients in 1992. Int J Tuberc Lung Dis1999;3:603-12. PMID:10423223
23. Winqvist N, Naucler A, Gomes V, Djamanca I, Koivula T, Jensen H et al. Threeyear follow-up of patients with pulmonary tuberculosis in Guinea-Bissau, West Africa. Int J Tuberc Lung Dis 2000;4:845-52. PMID:10985653
24. Cox H, Kebede Y, Allamuratova S, Ismailov G, Davletmuratova Z, Byrnes G et al. Tuberculosis recurrence and mortality after successful treatment: impact of drug resistance. PLoS Med 2006;3:e384. doi:10.1371/journal. pmed.0030384 PMID:17020405
25. Connolly C, Reid A, Davies G, Sturm W, McAdam KP, Wilkinson D. Relapse and mortality among HIV-infected and uninfected patients with tuberculosis successfully treated with twice weekly directly observed therapy in rural South Africa. AIDS 1999;13:1543-7. doi:10.1097/00002030-199908200-00015 PMID:10465079
26. Shean KP, Willcox PA, Siwendu SN, Laserson KF, Gross L, Kammerer S et al.Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 1992-2002. Int J Tuberc Lung Dis 2008;12:1182-9. PMID:18812049
27. Au-Yeung C, Kanters S, Ding E, Glaziou P, Anema A, Cooper CL et al. Tuberculosis mortality in HIV-infected individuals: a cross-national systematic assessment. Clin Epidemiol 2011;3:21-9. PMID:21326656
28. Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat. World population prospects: the2008revision. Available from: http://esa.un.org/unpp [accessed 3 August 2011].
29. Smith N, Denning DW. Underlying pulmonary disease frequency in patients with chronic pulmonary aspergillosis. Eur Respir J 2011;37:865-72. doi:10.1183/09031936.00054810 PMID:20595150
30. Felton TW, Baxter C, Moore CB, Roberts SA, Hope WW, Denning DW. Efficacy and safety of posaconazole for chronic pulmonary aspergillosis. Clin Infect Dis 2010;51:1383-91. doi:10.1086/657306 PMID:21054179
31. Kappe R, Schulze-Berge A, Sonntag HG. Evaluation of eight antibody tests and one antigen test for the diagnosis of invasive aspergillosis. Mycoses 1996;39:13-23. doi:10.1111/j.1439-0507.1996.tb00078.x PMID:8786752
32. Coleman RM, Kaufman L. Use of the immunodiffusion test in the serodiagnosis of aspergillosis. Appl Microbiol 1972;23:301-8. PMID:4622826
33. Longbottom JL, Pepys J, Clive FT. Diagnostic precipitin test in Aspergillus pulmonary mycetoma. Lancet 1964;1:588-9. doi:10.1016/S0140- 6736(64)91335-2 PMID:14104489
34. Severo LC, Geyer GR, Porto Nda S, Wagner MB, Londero AT. Pulmonary Aspergillus niger intracavitary colonization. Report of 23 cases and a review of the literature. Rev Iberoam Micol 1997;14:104-10. PMID:17655384
35. Pasqualotto AC, Denning DW. An aspergilloma caused by Aspergillus flavus. Med Mycol 2008;46:275-8. doi:10.1080/13693780701624639 PMID:17885955
36. Denning DW, Park S, Lass-Florl C, Fraczek MG, Kirwan M, Gore R et al. High-frequency triazole resistance found In nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis 2011;52:1123-9. doi:10.1093/cid/cir179 PMID:21467016
37. Regnard JF, Icard P, Nicolosi M, Spagiarri L, Magdeleinat P, Jauffret B et al. Aspergilloma: a series of 89 surgical cases. Ann Thorac Surg 2000;69:898-903. doi:10.1016/S0003-4975(99)01334-X PMID:10750780
38. Kim YT, Kang MC, Sung SW, Kim JH. Good long-term outcomes after surgical treatment of simple and complex pulmonary aspergilloma. Ann Thorac Surg 2005;79:294-8. doi:10.1016/j.athoracsur.2004.05.050 PMID:15620961
39. Pratap H, Dewan RK, Singh L, Gill S, Vaddadi S. Surgical treatment of pulmonary aspergilloma: a series of 72 cases. Indian J Chest Dis Allied Sci 2007;49:23-7. PMID:17256563
40. Brik A, Salem AM, Kamal AR, Abdel-Sadek M, Essa M, El Sharawy M et al. Surgical outcome of pulmonary aspergilloma. Eur J Cardiothorac Surg 2008;34:882-5. doi:10.1016/j.ejcts.2008.06.049 PMID:18701313
41. Vaid M, Kaur S, Sambatakou H, Madan T, Denning DW, Sarma PU. Distinct alleles of mannose-binding lectin (MBL) and surfactant proteins A (SP-A) in patients with chronic cavitary pulmonary aspergillosis and allergic bronchopulmonary aspergillosis. Clin Chem Lab Med 2007;45:183-6. doi:10.1515/CCLM.2007.033 PMID:17311505
42. Carvalho A, Pasqualotto AC, Pitzurra L, Romani L, Denning DW, Rodrigues F. Polymorphisms in toll-like receptor genes and susceptibility topulmonary aspergillosis. J Infect Dis 2008;197:618-21. doi:10.1086/526500 PMID:18275280
43. Kelleher P, Goodsall A, Mulgirigama A, Kunst H, Henderson DC, Wilson R et al. Interferon-γ therapy in two patients with progressive chronic pulmonary aspergillosis. Eur Respir J 2006;27:1307-10. doi:10.1183/0903193 6.06.00021705 PMID:16772392
44. Jain LR, Denning DW. The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. J Infect 2006;52:e133-7. doi:10.1016/j.jinf.2005.08.022 PMID:16427702
45. Sambatakou H, Dupont B, Lode H, Denning DW. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Am J Med 2006;119:527.e17-24.
46. Kohno S, Izumikawa K, Ogawa K, Kurashima A, Okimoto N, Amitani R et al.; Japan Chronic Pulmonary Aspergillosis Study Group (JCPASG). Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. J Infect 2010;61:410-8. doi:10.1016/j. jinf.2010.08.005 PMID:20797407